Redeye positively reviews the Thermo Fisher deal’s potential and the company’s US sales outlook. We raise our sales forecast on all time horizons and up our long-term EBIT assumptions, which increases our fair value range considerably. Devyser has finally started to get recognised for its strong sales and profitability prospects, but we argue that the share is far from fairly priced. The share is currently trading at a discount to peers despite ticking the boxes for a premium valuation, in our view.